The specter of generic rivalry has repeatedly loomed over copyright’s famous drug, Viagra, sparking questions about the prospects of similar medicinal portfolios. While initial periods saw impressive profits, the patent end has allowed the way for cheaper alternatives, potentially reducing earnings and creating a genuine hazard for stakeholders p